Drug Profile
CSL 111
Alternative Names: CSL-111; CSL111 (reconstituted HDL) - CSLLatest Information Update: 08 Jun 2010
Price :
$50
*
At a glance
- Originator CSL
- Class Cardiovascular therapies; Lipoproteins
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Stroke
Most Recent Events
- 26 Mar 2007 Results from a phase II clinical trial (ERASE) in patients with Acute Coronary Syndrome added to the adverse events and Ischaemic Heart Disease therapeutic trials sections ,
- 22 Nov 2006 Preclinical trials in Acute coronary syndromes in Europe (unspecified route)
- 14 Nov 2006 Preclinical trials in Acute coronary syndromes in Australia (unspecified route)